Author: admin

  • Norman Lamb – 2016 Parliamentary Question to the Department of Health

    Norman Lamb – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Norman Lamb on 2016-02-01.

    To ask the Secretary of State for Health, how many young people aged 17 or under of each age were treated in adult mental health wards in each if the last 10 years for which figures are available.

    Alistair Burt

    Whilst we do not have figures for how many young people were treated in adult mental health wards, the data below shows the number who were admitted to adult mental health wards for all available years. These figures may therefore include children who have been admitted when their parents are treated, e.g. a mother for a perinatal mental health condition.

    Age

    2011/12

    2012/13

    2013/14

    2014/15

    Total aged 17 and under

    357

    219

    355

    391

    0

    –

    1

    –

    2

    1

    –

    –

    –

    –

    2

    –

    –

    –

    –

    3

    –

    –

    –

    –

    4

    –

    –

    –

    –

    5

    –

    –

    –

    2

    6

    –

    –

    –

    2

    7

    –

    –

    –

    2

    8

    –

    –

    –

    3

    9

    –

    –

    –

    3

    10

    –

    –

    –

    3

    11

    –

    –

    –

    3

    12

    1

    1

    2

    8

    13

    3

    2

    3

    8

    14

    11

    5

    9

    8

    15

    32

    14

    29

    31

    16

    100

    51

    104

    106

    17

    210

    145

    208

    210

    The Mental Health Act 2007 introduced new provisions, in effect since April 2010, to help ensure that patients under the age of 18 are accommodated in an environment that is suitable for their age. Young people are all individual, however, and some in the 16 to 18 age group may feel more comfortable in adult wards. Services should take into account the individual’s needs and preferences.

    There are now more inpatient Child and Adolescent Mental Health Services inpatient beds (‘Tier 4’) than ever before.

  • Danny Kinahan – 2016 Parliamentary Question to the Department of Health

    Danny Kinahan – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Danny Kinahan on 2016-02-01.

    To ask the Secretary of State for Health, with reference to the Answer of 28 January 2016 to Question 23467, what progress has been made on the procurement of the HPV vaccine.

    Jane Ellison

    The Department is considering the Joint Committee on Vaccination and Immunisation’s advice on this potential programme. Following this, consideration will be given to the procurement of vaccine.

  • Norman Lamb – 2016 Parliamentary Question to the Department of Health

    Norman Lamb – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Norman Lamb on 2016-02-01.

    To ask the Secretary of State for Health, how many incidences of (a) restraint and (b) prone restraint in child and adolescent mental health services were recorded in each of the last 10 years for which figures are available.

    Alistair Burt

    While this information is not yet collected centrally, from 1 January 2016 mental health providers are required to record all incidents of restraint involving children and young people in their returns to the Health and Social Care Information Centre. This data will become available as soon thereafter as data quality allows. The Care Quality Commission is responsible for monitoring practice in inpatient children and adolescent psychiatric services.

  • Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Greg Mulholland on 2016-02-01.

    To ask the Secretary of State for Health, what arrangements there are for negotiating national prices for rare disease drugs that are not reviewed by NICE.

    George Freeman

    The prices of branded medicines to the health service, including those for rare disease drugs, are controlled by a voluntary and statutory scheme. The 2014 Pharmaceutical Price Regulation Scheme (PPRS) agreed a fixed level of growth on the vast majority of National Health Service spend on branded medicines with additional expenditure above this level paid for by the pharmaceutical companies. Over the first three years of the 2014 PPRS the UK Health services are expected to get back almost £1.8 billion in PPRS payments.

    It is NHS England’s responsibility to develop commissioning policies for treatments provided as part of prescribed specialised services, including some medicines for rare diseases. As part of the development of such policies, NHS England may take into account commercial offers manufacturers may make to the NHS. The Accelerated Access Review is looking with the National Institute for Health and Care Excellence at a range of new mechanisms for drug reimbursement adaptive pathways and managed access agreements.

  • Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    Greg Mulholland – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Greg Mulholland on 2016-02-01.

    To ask the Secretary of State for Health, when NHS England next plans to review the process and practice of applications for individual funding requests.

    George Freeman

    NHS England will be consulting on a revised Individual Funding Request policy later this year and will subsequently review and update the Standard Operating Procedure as required.

  • Barry Sheerman – 2016 Parliamentary Question to the Department of Health

    Barry Sheerman – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Barry Sheerman on 2016-02-01.

    To ask the Secretary of State for Health, what steps his Department is taking to improve the diagnosis and treatment of lipoedema.

    Jane Ellison

    No such analysis has been made.

    There are several different treatments available for the management of lipoedema such as compression therapy, exercise and massage. There is limited evidence on the efficacy of liposuction for the treatment of lipoedema, and it is not routinely available on the National Health Service.

    In May 2014, the Royal College of General Practitioners, in partnership with the charity Lipoedema UK, developed and published an e-learning module for general practitioners on the diagnosis and management of lipoedema. The module was endorsed by the Royal College of Nursing and can be found at the following link:

    elearning.rcgp.org.uk/course/info.php?id=146&popup=0

    “

  • Rosie Cooper – 2016 Parliamentary Question to the Department of Health

    Rosie Cooper – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Rosie Cooper on 2016-02-01.

    To ask the Secretary of State for Health, what plans the Government has to introduce a prostate cancer screening programme.

    Jane Ellison

    The UK National Screening Committee (UK NSC) recently examined and consulted upon the international peer reviewed evidence regarding prostate cancer screening. The UK NSC recommended against a systematic population screening programme for prostate cancer. This is because the prostate-specific antigen (PSA) is not an accurate enough test for prostate cancer. Additionally, the UK NSC identified that there is still an incomplete understanding of which prostate cancers are aggressive and require treatment and which are safe to actively monitor. There is a significant amount of research activity underway, but currently the evidence suggests that a systematic screening programme would do more harm than good.

  • Greg Knight – 2016 Parliamentary Question to the Department of Health

    Greg Knight – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Greg Knight on 2016-02-01.

    To ask the Secretary of State for Health, if he will make an assessment of the implications for his policies on managing risks to public health from bisphenol A in food and drinks sold in plastic containers of the decision of the Canadian government to ban such containers.

    Jane Ellison

    We are advised by the Food Standards Agency, which has responsibility for food safety, that the United Kingdom’s view remains that exposure to Bisphenol A (BPA) from food contact materials does not represent a risk to consumers.

    In January 2015, the European Food Safety Authority (EFSA) published its latest re-evaluation of BPA exposure and toxicity. EFSA’s experts concluded that BPA poses no health risk to consumers of any age group (including unborn children, infants and adolescents) at current exposure levels from food contact materials.

  • Greg Knight – 2016 Parliamentary Question to the Department of Health

    Greg Knight – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Greg Knight on 2016-02-01.

    To ask the Secretary of State for Health, what research his Department has undertaken or commissioned into the effect on humans of high levels of bisphenol A caused by consuming food and drinks sold in some plastic containers; and if he will make a statement.

    Jane Ellison

    We are advised by the Food Standards Agency, which has responsibility for food safety, that the United Kingdom’s view remains that exposure to Bisphenol A (BPA) from food contact materials does not represent a risk to consumers.

    In January 2015, the European Food Safety Authority (EFSA) published its latest re-evaluation of BPA exposure and toxicity. EFSA’s experts concluded that BPA poses no health risk to consumers of any age group (including unborn children, infants and adolescents) at current exposure levels from food contact materials.

  • Barry Sheerman – 2016 Parliamentary Question to the Department of Health

    Barry Sheerman – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Barry Sheerman on 2016-02-01.

    To ask the Secretary of State for Health, whether his Department has conducted an analysis of the potential cost to the public purse of offering liposuction treatment for lipoedema through the NHS.

    Jane Ellison

    No such analysis has been made.

    There are several different treatments available for the management of lipoedema such as compression therapy, exercise and massage. There is limited evidence on the efficacy of liposuction for the treatment of lipoedema, and it is not routinely available on the National Health Service.

    In May 2014, the Royal College of General Practitioners, in partnership with the charity Lipoedema UK, developed and published an e-learning module for general practitioners on the diagnosis and management of lipoedema. The module was endorsed by the Royal College of Nursing and can be found at the following link:

    elearning.rcgp.org.uk/course/info.php?id=146&popup=0

    “